Abdel-Wahab Omar, Levine Ross L
Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10065 USA.
F1000 Med Rep. 2010 Jul 22;2:55. doi: 10.3410/M2-55.
Acute myeloid leukemia (AML) is a disorder with significant molecular and clinical heterogeneity. Although there have been clear advances in the identification of somatic genetic and epigenetic alterations present in the malignant cells of patients with AML, translating this knowledge into an integrated view with an impact on the clinical treatment of AML has been slower to evolve. Recent clinical advances in the treatment of AML include studies demonstrating the benefit of dose-intense daunorubicin therapy in induction chemotherapy for patients of any age. We also review use of the DNA methyltransferase inhibitor azacitidine for treatment of AML in elderly patients as well as a study of global patterns of DNA methylation in patients with AML. Lastly, we review a recent assessment of the role of allogeneic hematopoietic stem cell transplantation in AML in first complete remission.
急性髓系白血病（AML）是一种具有显著分子和临床异质性的疾病。尽管在识别AML患者恶性细胞中存在的体细胞遗传和表观遗传改变方面已经取得了明显进展，但将这些知识转化为对AML临床治疗有影响的综合观点的进展却较为缓慢。AML治疗的近期临床进展包括一些研究，这些研究表明剂量密集型柔红霉素疗法在各年龄段患者的诱导化疗中具有益处。我们还综述了DNA甲基转移酶抑制剂阿扎胞苷用于老年AML患者治疗的情况以及一项关于AML患者DNA甲基化全球模式的研究。最后，我们综述了近期对异基因造血干细胞移植在AML首次完全缓解中的作用的评估。
